Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. - sprookjes - yvandenbroek - TriplyDB

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

http://www.wikidata.org/entity/Q33401766

about

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)Acute myeloid leukemia in the older adults A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials Update on rational targeted therapy in AML Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies An update of current treatments for adult acute myeloid leukemia Volasertib for AML: clinical use and patient consideration Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy Post-remission therapy for acute myeloid leukemia DNA demethylation and invasive cancer: implications for therapeutics Clinical Results of Hypomethylating Agents in AML Treatment Progress in acute myeloid leukemia Predicting response to epigenetic therapy IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy 'Acute myeloid leukemia: a comprehensive review and 2016 update'Advancements in the delivery of epigenetic drugs Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Decitabine: a review of its use in older patients with acute myeloid leukaemia.REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematology Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Acute myeloid leukemia: 2014 update on risk-stratification and management.

P2860

Q24628329-07784769-A525-4FBC-A74B-34EE30E1EC1D Q26740584-3F7AFB28-8413-4767-9433-3825338FE11F Q26743743-2239B55B-4993-43BD-BF32-4E92F1788E19 Q26745731-2C7CBED4-0A3B-4978-BF4C-41F308864094 Q26766152-F564A276-F607-4A53-B681-A9E958946E2C Q26770391-7FB96127-7134-4A4E-AE78-E9813F065589 Q26772235-C2416662-7C71-47B7-A38A-DD5E0753E701 Q26776396-0B534169-7177-42F2-BB11-EE531905CB89 Q26801131-0F42739D-390F-46CA-8EFF-249F6A837AE7 Q26991736-A37494D1-EBE7-4521-9EA7-A5A8C8219993 Q26995867-0C0F56F6-93BD-4833-B981-E17D34F8B337 Q27011914-D5C61192-CC18-440B-BC9B-B8C5576D546B Q27022725-B6FBF98F-9308-4AC2-9FCF-CE20EA0AEBB4 Q27024006-B67E5EC8-CAAA-4317-A18D-CEE1B075C3E7 Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C Q28066926-C6306FF8-652C-4190-90CE-7DD3C963C0D1 Q28070090-6AC67453-05A2-47F9-B523-2094D709A70D Q28072539-2BF5F4C9-550C-4019-9A6A-9F2EC8E8473E Q28088478-AE38195B-E8D9-42E4-9188-B70F0EAE1756 Q33163717-C67F3B39-2D6A-42BE-A58E-5CCFE028090B Q33403865-D0539382-4784-4EBB-8886-CFE2538CCE34 Q33406770-7C61F050-1E37-46AD-AA6D-55DCC43F6C14 Q33407030-9B7B3AAA-C5CD-4BE5-B42B-9CE2354F08C0 Q33418735-90906526-286F-4B21-8A3B-D9C02E48FC8C Q33424306-2EF03CCD-CA52-4812-AC15-1A1170AC8759 Q33431584-1AA8E06D-858A-425A-BF99-6A993A22EC4E Q33657377-58F39A50-6600-47FE-AADB-0B05C7F6B253 Q33702412-FB457FC3-7F17-4EF5-BD6D-6D6222706697 Q33761979-D391198E-5AC3-4A46-A6B8-F1A7EB3286E8 Q33903024-2FC67210-6891-47A7-8D0E-FD6111475EB5 Q33995598-6EEDEF37-F4D7-4EEE-8908-E0F745B5D607 Q34044905-5F16C8AD-0E3A-4B34-8003-2A9D97536795 Q34106830-869E3544-5328-44C3-B0E1-0654293CD911 Q34342944-4ABF96A1-5DFC-4907-8E79-36E750BCFEBD Q34350209-F6F33008-71F3-444B-B05F-7E152AD8D4C3 Q34395179-1E8D720C-4D97-4AD1-9185-A60DD87F684A Q34587614-4E47FE00-171B-4399-B476-8C306AB70B30 Q34655572-957D4DA1-AB87-4C48-8106-477C6BE331EE Q34661033-5CB7546B-5267-46DF-B033-821127A142AA Q34665691-00373E8A-A09A-42E3-8021-0192E0DBD9E8

P2860

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

http://www.wikidata.org/entity/Q33401766

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@ast

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@en

type

label

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@ast

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@en

prefLabel

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@ast

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@en

P1433

Q33401766-CBB11EC9-7544-4631-B2E7-EDB112D026C8

P1476

Q33401766-F03EEB8C-0F08-47F8-8272-9756D77B660E

P2093

Q33401766-178DE1F4-D01C-43CA-A338-7AB60AA727EE

Q33401766-2C2D98C5-B742-4DB0-AAFB-52337E27DB2C

Q33401766-3EF2BA17-6EC3-4BC8-A99C-CC0C8417EE9A

Q33401766-4FA6EBA3-FE5A-4992-A465-6793971C85BC

Q33401766-682299D2-EE80-4E55-BB0B-18F4D1E1C39F

Q33401766-6B1E6ECB-E311-41A1-AC54-EA162A9904AC

Q33401766-93E9689E-FBC0-46BF-A470-67AA5E224B36

Q33401766-B5D9EB09-48D1-490B-B4A9-C61EF87120B0

Q33401766-BB4EDC03-577B-4923-80BD-CA8F959912AB

Q33401766-CAFD6BA9-F293-4B89-8A9A-943CEA3C2D20

P2860

Q33401766-0D0E9553-98C9-4FD5-B683-484BA99D75FB

Q33401766-167D7076-9AF4-46B6-A61B-DCB5F59D81DF

Q33401766-486A9565-8FA5-4BAB-8B98-9CA5127BEB69

Q33401766-5167832F-3DDB-4C61-B3F9-70A05CA0E5F1

Q33401766-5CBFA54B-0A03-499A-9A04-AE32C4316C18

Q33401766-63BE6344-1B29-453A-961B-FE88F4C5F147

Q33401766-685B8BCB-16F6-4EE0-869D-0DA8D4141F43

Q33401766-6C5F6D30-38B6-4C2D-99FB-D5F28056FB7B

Q33401766-72CD13DB-2665-4D00-929E-940FFA81414B

Q33401766-94E268EA-F88F-458E-9438-290C53C6AE97

P304

Q33401766-BEA88808-7AE9-4AA8-A1BD-DAA4822CE27C

P31

Q33401766-1238D8A5-050C-4877-A22A-83CD691D86B4

P356

Q33401766-2C0163AC-88DF-44EC-9E40-F540ACF9F8AE

P407

Q33401766-5359AF12-2C52-45BE-9B7D-F8FACC98461D

P433

Q33401766-3A086206-9966-4DE7-9A78-6C6DCC02373F

P478

Q33401766-BBD27240-3D16-4FF9-96EE-6452E360F6FB

P50

Q33401766-4C0D69C8-0722-4152-AFAE-611865904D74

Q33401766-65BD4A80-8BFC-43BE-9144-49F3078E7804

Q33401766-744A6B59-6F61-4057-B978-A1B4E598368F

Q33401766-B60EDCA3-B1CE-41F2-916B-FD4A0ACDF419

Q33401766-BBF9128E-456F-41DC-8BA9-9DCA187E2277

Q33401766-E1A43D3A-F9A8-4470-9CAA-3FCE0B3D8E12

P577

Q33401766-AA57E996-0D65-4F66-BD84-22A107595F20

P698

Q33401766-719730E0-9202-4F28-801D-392BEE71BA9A

P921

Q33401766-3922718E-BFE8-4809-802B-ACD7A8FA6171

Q33401766-4C9B8393-246F-4329-99D7-F08D47F1F782

Q33401766-CA4DD3C4-B5F7-48E8-B8A4-572A8F882668

Q33401766-D2A71686-78E7-4D5F-8828-57DA9727DFC6

P932

Q33401766-EE112D16-13DE-46C9-AF10-B520225B2C05

P356

JCO.2011.38.9429

P1433

Journal of Clinical Oncology

P1476

Multicenter, randomized, open- ...... gnosed acute myeloid leukemia.

@en

P2093

Agnieszka Wierzbowska

http://www.w3.org/2001/XMLSchema#string

Ching-Yuan Kuo

http://www.w3.org/2001/XMLSchema#string

Christopher Arthur

http://www.w3.org/2001/XMLSchema#string

Daniel Lysák

http://www.w3.org/2001/XMLSchema#string

Grzegorz Mazur

http://www.w3.org/2001/XMLSchema#string

Jacques Delaunay

http://www.w3.org/2001/XMLSchema#string

Jaroslav Cermak

http://www.w3.org/2001/XMLSchema#string

Jiri Mayer

http://www.w3.org/2001/XMLSchema#string

Jyh-Pyng Gau

http://www.w3.org/2001/XMLSchema#string

Mark Minden

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Cancer statistics, 2010

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Epidemiology of hematological malignancies.

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.

P304

2670-2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.38.9429

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Anna Dmoszyńska

P577

2012-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22689805

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

multicenter trial

P932

4874148

http://www.w3.org/2001/XMLSchema#string